CelLBxHealth PLC has signed a master services agreement with AstraZeneca, enabling it to provide circulating tumour cell (CTC) analytics for AstraZeneca's drug discovery and development. Using its Parsortix platform, CelLBxHealth will analyze CTCs from clinical trial samples to offer insights into cancer progression and treatment response. This agreement covers AstraZeneca's entire development pipeline, expanding CelLBxHealth's role beyond a single program. The partnership aims to deliver strong and productive outcomes in cancer research and drug development.
T. Rowe Price emphasizes the growing risk of US market concentration in a few mega-cap stocks, now making up 32% of the S&P 500. The firm points to international equities as a promising alternative, noting they trade at a 23% forward P/E discount and...
AstraZeneca, in partnership with Secaro and ERM, is launching a Clean Heat Program to decarbonize industrial heat across its supply chain, aiming to reduce emissions and stabilize costs amid volatile natural gas prices. Industrial heat, a major sourc...
